Menu

Regulatory

 

First-in-health regulatory changes Kirsten Messmer

Seeking ways to ensure participant safety in first-in-human trials

Kirsten Messmer, Ph.D., R.A.C., principal regulatory affairs specialist, details changes in regulatory guidelines for first-in-human trials.

Read more...
 

Brexit’s potential regulatory impact on the pharmaceutical industry

Brexit's potential regulatory impact on the pharmaceutical industry

Regulatory affairs experts at PPD, Alistair Davidson and Vincenzo Cannizzaro, reflect on how the United Kingdom's departure from the European Union might impact the pharmaceutical industry.

Read more...
 

Major clinical trial reforms underway in China’s regulatory environment thumbnail image

Major clinical trial reforms underway in China's regulatory environment

Bill Wang, director of regulatory affairs, discusses China's regulatory environment in the second-largest pharmaceutical market in the world.

Read more...
Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.